

#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Povalties: Funds are coming in to you or your institution due to you



| Section 1. Identifying Inform   | nation                                 |                             |  |  |  |  |  |
|---|--|-----------------------------|--|--|--|--|--|
| 1. Given Name (First Name)<br>Yasushi   | 2. Surname (Last Name)<br>Hasegawa     | 3. Date<br>24-November-2020 |  |  |  |  |  |
| 4. Are you the corresponding author?  | ✓ Yes No                               |                             |  |  |  |  |  |
| 5. Manuscript Title<br>Does laparoscopic resection for colorectal cancer liver metastasis have a long-term oncologic advantage?   |  |                             |  |  |  |  |  |
| 6. Manuscript Identifying Number (if you k  | now it)                                |                             |  |  |  |  |  |
|   |  |                             |  |  |  |  |  |
| Section 2. The Work Under C   | onsideration for Publication           |                             |  |  |  |  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for<br>any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation,<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of interest? Yes V No   |  |                             |  |  |  |  |  |
| Section 3. Relevant financial   | activities outside the submitted work. |                             |  |  |  |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> . Are there any relevant conflicts of interest? Yes $\checkmark$ No |  |                             |  |  |  |  |  |
| Section 4. Intellectual Prope   | rty Patents & Convrights               |                             |  |  |  |  |  |

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Ves



## Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

## Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Hasegawa has nothing to disclose.

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



| Section 1. Identifying Inform   | nation                           |   |  |  |  |  |
|---|----------------------------------|---|--|--|--|--|
| 1. Given Name (First Name)<br>Minoru  | 2. Surname (Last Name)<br>Kitago | 3. Date<br>24-November-2020                     |  |  |  |  |
| 4. Are you the corresponding author?  | Yes 🖌 No                         | Corresponding Author's Name<br>Yasushi Hasegawa |  |  |  |  |
| 5. Manuscript Title<br>Does laparoscopic resection for colored  | ctal cancer liver metastasis     | have a long-term oncologic advantage?           |  |  |  |  |
| 6. Manuscript Identifying Number (if you k  | now it)                          |   |  |  |  |  |
|   |                                  | -   |  |  |  |  |
| Section 2. The Work Under C   | onsideration for Public          | cation  |  |  |  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for<br>any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation,<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of interest? Yes V No   |                                  |   |  |  |  |  |
| Section 3. Relevant financial   | activities outside the s         | ubmitted work.                                  |  |  |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> . Are there any relevant conflicts of interest? Yes $\checkmark$ No |                                  |   |  |  |  |  |
| Section 4. Intellectual Prope   | rty Patents & Copyrid            | uhts  |  |  |  |  |

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V No



## Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

## Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Kitago has nothing to disclose.

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



| Section 1. Identifying Inform   | nation  |  |  |  |  |  |
|---|---|--|--|--|--|--|
| 1. Given Name (First Name)<br>Yuta  | 2. Surname (Last Name)<br>Abe   | 3. Date<br>24-November-2020  |  |  |  |  |
| 4. Are you the corresponding author?  | Yes 🖌 No  | Corresponding Author's Name<br>Yasushi Hasegawa  |  |  |  |  |
| 5. Manuscript Title<br>Does laparoscopic resection for colore   | ctal cancer liver metastasis  | have a long-term oncologic advantage?  |  |  |  |  |
| 6. Manuscript Identifying Number (if you k  | now it)   |  |  |  |  |  |
|   |   | _  |  |  |  |  |
| Section 2. The Work Under C   | Consideration for Publi   | cation   |  |  |  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for<br>any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation,<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of interest? Yes Yes No |   |  |  |  |  |  |
| Section 3. Relevant financia  | l activities outside the  | submitted work.  |  |  |  |  |
| Place a check in the appropriate boxes of compensation) with entities as desc   | in the table to indicate wh<br>ribed in the instructions. U<br>port relationships that we | ether you have financial relationships (regardless of amount<br>se one line for each entity; add as many lines as you need by<br>re <b>present during the 36 months prior to publication</b> . |  |  |  |  |
| Section 4. Intellectual Prope   | erty Patents & Copyri   | ghts   |  |  |  |  |

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V



# Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

## Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Abe has nothing to disclose.

#### **Evaluation and Feedback**



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## 1. Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Povalties: Funds are coming in to you or your institution due to you



| . Given Name (First Name)             | 2. Surname (Last Name)      |                                | 3. Date          |
|---------------------------------------|-----------------------------|--------------------------------|------------------|
| ıko                                   | Kitagawa                    |                                | 24-November-2020 |
| . Are you the corresponding author?   | Yes 🖌 No                    | Corresponding Author's Nan     | ne               |
|                                       |                             | Yasushi Hasegawa               |                  |
| Manuscript Title                      |                             |                                |                  |
| es laparoscopic resection for color   | ectal cancer liver metastas | sis have a long-term oncologic | advantage?       |
| Manuscript Identifying Number (if you | know it)                    |                                |                  |

# Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

🖌 No

| Are there any relevant conflicts of interest? | Yes |
|---|-----|
|---|-----|

# Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? Yes No

If yes, please fill out the appropriate information below.

| Name of Entity                  | Grant?       | Personal<br>Fees <b>?</b> | Non-Financial<br>Support? | Other? | Comments |  |
|---------------------------------|--------------|---------------------------|---------------------------|--------|----------|--|
| ASAHI KASEI PHARMA CORPORATION  | $\checkmark$ | $\checkmark$              |                           |        |          |  |
| TAIHO PHARMACEUTICAL CO., LTD   | $\checkmark$ | $\checkmark$              |                           |        |          |  |
| CHUGAI PHARMACEUTICAL CO., LTD. | $\checkmark$ | $\checkmark$              |                           |        |          |  |
| DAIICHI SANKYO COMPANY, LIMITED | $\checkmark$ |                           |                           |        |          |  |
| Merck Serono Co., Ltd.          | $\checkmark$ |                           |                           |        |          |  |
| EA Pharma Co., Ltd.             | $\checkmark$ | $\checkmark$              |                           |        |          |  |
| Yakult Honsha Co. Ltd.          | $\checkmark$ | $\checkmark$              |                           |        |          |  |
| Otsuka Pharmaceutical Co., Ltd. | $\checkmark$ | $\checkmark$              |                           |        |          |  |



| Name of Entity                           | Grant?       | Personal<br>Fees | Non-Financial<br>Support? | Other? | Comments |  |
|--|--------------|------------------|---------------------------|--------|----------|--|
| Takeda Pharmaceutical Co., Ltd.          | $\checkmark$ |                  |                           |        |          |  |
| Otsuka Pharmaceutical Factory Inc.       | $\checkmark$ | $\checkmark$     |                           |        |          |  |
| SHIONOGI & CO., LTD.                     | $\checkmark$ | $\checkmark$     |                           |        |          |  |
| KAKEN PHARMACEUTICAL CO.,LTD.            | $\checkmark$ |                  |                           |        |          |  |
| Kowa Pharmaceutical Co., Ltd.            | $\checkmark$ |                  |                           |        |          |  |
| Astellas Pharma Inc.                     | $\checkmark$ | $\checkmark$     |                           |        |          |  |
| MEDICON INC.                             | $\checkmark$ |                  |                           |        |          |  |
| DAINIPPON SUMITOMO PHARMA Co., Ltd.      | $\checkmark$ | $\checkmark$     |                           |        |          |  |
| Taisho Toyama Pharmaceutical Co., Ltd.   | $\checkmark$ | $\checkmark$     |                           |        |          |  |
| Kyouwa Hakkou Kirin Co., Ltd.            | $\checkmark$ |                  |                           |        |          |  |
| Pfizer Japan Inc.                        | $\checkmark$ |                  |                           |        |          |  |
| ONO PHARMACEUTICAL CO., LTD.             | $\checkmark$ | $\checkmark$     |                           |        |          |  |
| NIHON PHARMACEUTICAL CO., LTD.           | $\checkmark$ | $\checkmark$     |                           |        |          |  |
| Japan Blood Products Organization        | $\checkmark$ |                  |                           |        |          |  |
| Medtronic Japan Co., Ltd.                | $\checkmark$ |                  |                           |        |          |  |
| Sanofi K.K., grants from Eisai Co., Ltd. | $\checkmark$ | $\checkmark$     |                           |        |          |  |
| TSUMURA & CO.                            | $\checkmark$ |                  |                           |        |          |  |
| KCI Licensing, Inc.                      | $\checkmark$ |                  |                           |        |          |  |
| ABBOTT JAPAN CO., LTD.                   | $\checkmark$ |                  |                           |        |          |  |
| FUJIFILM Toyama Chemical Co., Ltd.       | $\checkmark$ |                  |                           |        |          |  |
| Nippon Covidien Inc.                     | $\checkmark$ |                  |                           |        |          |  |

**Section 4.** 

#### Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?

🖌 No



## Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

## Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Kitagawa reports grants from Ono Pharmaceutical Co., Ltd, grants from Bristol-Myers Squibb, during the conduct of the study; grants and personal fees from ASAHI KASEI PHARMA CORPORATION, grants and personal fees from TAIHO PHARMACEUTICAL CO., LTD, grants and personal fees from CHUGAI PHARMACEUTICAL CO., LTD., grants from DAIICHI SANKYO COMPANY, LIMITED, grants from Merck Serono Co., Ltd., grants and personal fees from EA Pharma Co., Ltd., grants and personal fees from Yakult Honsha Co. Ltd., grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants from Takeda Pharmaceutical Co., Ltd., grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants from Takeda Pharmaceutical Co., Ltd., grants and personal fees from SHIONOGI & CO., LTD. , grants from KAKEN PHARMACEUTICAL CO.,LTD., grants from Kowa Pharmaceutical Co., Ltd., grants and personal fees from Taisho Toyama Pharmaceutical Co., Ltd., grants from KJUITOMO PHARMA Co., Ltd., grants and personal fees from Taisho Toyama Pharmaceutical Co., Ltd., grants from Kyouwa Hakkou Kirin Co., Ltd., grants from Pfizer Japan Inc., grants and personal fees from ONO PHARMACEUTICAL CO., LTD., grants from Medtronic Japan Co., Ltd., grants and personal fees from Sanofi K.K., grants from Eisai Co., Ltd., grants from TSUMURA & CO., grants from KCI Licensing, Inc., grants from ABBOTT JAPAN CO., LTD., grants from FUJIFILM Toyama Chemical Co., Ltd. , grants from ABBOTT JAPAN CO., LTD., grants from FUJIFILM Toyama Chemical Co., Ltd. , grants from Nippon Covidien Inc., outside the submitted work; .

#### **Evaluation and Feedback**